Overview

* X4 Pharmaceuticals ( XFOR ) Q3 net loss narrows to $29.8 mln from $36.7 mln yr ago

* Company raised $240.3 mln in financing, extending cash runway to end of 2028

* X4 Pharmaceuticals ( XFOR ) reports $13 mln annualized cost savings from workforce reduction

Outlook

* X4 expects to complete 4WARD trial enrollment by Q3 2026

* Company's cash runway extends to end of 2028

* X4 plans to launch mavorixafor for chronic neutropenia by end of 2028

* Workforce reduction expected to save $13 mln annually

Result Drivers

* NET LOSS - Net loss for the three months ended September 30, 2025 was $29.8 million, or $0.69 for basic and diluted loss per share, compared to net loss of $36.7 million, or $5.48 for basic and diluted loss per share, for the same period in 2024

* FINANCIAL STRENGTHENING - Raised $240.3 mln in financings, extending cash runway

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.69

Q3 Net -$29.81

Income mln

Q3 -$27.50

Income mln

from

Operatio

ns

Q3 $29.27

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for X4 Pharmaceuticals Inc ( XFOR ) is $9.00, about 55.9% above its November 4 closing price of $3.97

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)